Stock News•2 months ago
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NeuroPace's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
MarketLens
Neuronetics: A High-Stakes Turnaround Play with 143% Upside Potential
3 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•3 months ago
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
BrainsWay's Q1-2026 revenue rose 35% YoY, with a 75% gross margin, after expanding its capital-light leasing model. FY-2026 revenue is expected at $66–68M, with adjusted EBITDA growth of 86–100%.
Stock News•3 months ago
Neuronetics and Jorey Chernett Announce Shared Vision
Neuronetics and second-largest shareholder Jorey Chernett announced a constructive alignment framework with the Board and management, potentially easing governance friction and supporting strategic ex...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•31 minutes ago
Nvidia's succession dilemma just got real. Here's who could take over if Jensen Huang steps down.
Stock News•37 minutes ago
Nvidia's Jensen Huang could face major trouble when Dems take control of Congress: ‘No way this guy survives'
Stock News•38 minutes ago
Rep. Gimenez Says Nvidia Affair Raises Security Concerns
Stock News•50 minutes ago
Why Nvidia Stock Was Down Today
Stock News•52 minutes ago